Aurobindo Pharma shares in focus after Q3 profit drops 10% YoY. Should you buy or sell?

Aurobindo Pharma shares will be in focus on Friday after the company reported a 10% year-on-year (YoY) decline in net profit to Rs 846 crore for the third quarter ended December 2023, impacted by weaker US sales despite strong growth in Europe, growth markets, and the antiretrovirals segment.

The…